Shares of Intrexon Corp (NYSE:XON) have been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $31.67.
A number of research firms have recently issued reports on XON. Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Thursday, August 16th. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. Stifel Nicolaus began coverage on shares of Intrexon in a research report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 price target on the stock. Finally, Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target on the stock. in a research report on Monday, July 16th.
In other news, insider Helen Sabzevari sold 8,402 shares of the firm’s stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the transaction, the insider now directly owns 25,000 shares in the company, valued at approximately $363,500. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 48.20% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Peregrine Capital Management LLC increased its holdings in shares of Intrexon by 15.7% in the 2nd quarter. Peregrine Capital Management LLC now owns 711,266 shares of the biotechnology company’s stock worth $9,915,000 after acquiring an additional 96,393 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Intrexon in the 2nd quarter worth about $457,000. Wellington Shields & Co. LLC increased its holdings in shares of Intrexon by 9.7% in the 2nd quarter. Wellington Shields & Co. LLC now owns 335,600 shares of the biotechnology company’s stock worth $4,678,000 after acquiring an additional 29,600 shares during the period. Peloton Wealth Strategists increased its holdings in shares of Intrexon by 12.7% in the 2nd quarter. Peloton Wealth Strategists now owns 39,900 shares of the biotechnology company’s stock worth $556,000 after acquiring an additional 4,500 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Intrexon by 9.7% in the 1st quarter. Northern Trust Corp now owns 411,324 shares of the biotechnology company’s stock worth $6,305,000 after acquiring an additional 36,508 shares during the period. 84.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of Intrexon stock traded up $0.31 during trading hours on Friday, reaching $16.49. The company’s stock had a trading volume of 1,251,249 shares, compared to its average volume of 1,583,386. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.78. Intrexon has a one year low of $10.26 and a one year high of $20.35. The company has a market cap of $2.47 billion, a P/E ratio of -17.92 and a beta of 1.09.
Intrexon (NYSE:XON) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The business had revenue of $45.30 million during the quarter, compared to the consensus estimate of $51.70 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. As a group, sell-side analysts predict that Intrexon will post -0.79 earnings per share for the current year.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Story: How to Invest in an Index Fund
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.